Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

Douglas, Kenneth; Parker, Anne; Hayden, Patrick; Rahemtulla, Amin; D'Addio, Alessandra; Lemoli, Roberto M.; Rao, Kamakshi V.; Maris, Michael B.; Pagliuca, Antonio; Uberti, Joseph P.; Scheid, Christoph; Noppeney, Richard; Cook, Gordon; Bokhari, Syed W; Worel, Nina; Mikala, Gábor; Masszi, Tamás; Taylor, Robert L.; Treisman, Jonathan

doi:10.1038/bmt.2011.9

Cited by 20 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this view, results from a small series of patients with advanced renal failure indicate that plerixafor may be safely used at full dosage to mobilize PBSCs in this difficult patient group. 37 Overall, these findings confirm the safety profile of plerixafor after chemotherapy.…”

Section: Tablesupporting

confidence: 77%

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

D'Addio

Curti

Worel

et al. 2010

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Section: Tablesupporting

confidence: 77%

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

D'Addio

Curti

Worel

et al. 2010

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

“…Two studies included patients with MM exclusively. 23,24 In one of these, 24 the objective was to evaluate the safety and efficacy of plerixafor in patients with MM and renal failure. One study included only patients with lymphoma.…”

Section: Literature Reviewmentioning

confidence: 99%

A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program

Sheppard

Bredeson

Huebsch

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

Plerixafor effectively mobilizes hematopoietic stem cells (HSCs). However, most patients' cells are successfully collected using traditional strategies and there is limited cost-effectiveness data. The objectives of this study were to: (1) summarize the published reports of mobilization using a plerixafor-based strategy during compassionate access programs and (2) describe the Canadian experience with plerixafor during its availability by Health Canada's Special Access Program. A literature search identified reports of plerixafor-based mobilization during compassionate access programs. Overall, successful collection of at least 2 × 10 6 CD34+ cells/ kg was achieved in~75% of patients, and about two-thirds of patients went on to HSCT. A greater proportion of patients had successful collections when plerixafor was used in the upfront or preemptive settings. Plerixafor was made available by Health Canada's SAP from September 2008 to December 2010. In 96 of 132 (73%) patients, there was successful collection of at least 2 × 10 6 CD34+ cells/kg. Ninety-nine (75%) patients went on to receive an autologous transplant. Plerixafor-based mobilization is effective in perceived poor mobilizers. The optimal way to incorporate plerixafor into a mobilization strategy, however, remains to be determined. Centre-specific analysis of resource utilization may help to identify the most cost-effective way to implement various plerixafor-based mobilization strategies.

show abstract

“…83,91,99 The limited post-marketing experience suggests that plerixafor mainly at a dose of 160 mg/kg can be safely and efficiently conjugated to G-CSF for PBPC mobilization in patients with advanced-stage renal failure on hemodialysis. 100,101 Normal donors In accordance with the initial studies of plerixafor in healthy volunteers, the pivotal study by Devine et al 102 demonstrated safe and successful mobilization of healthy matched sibling donors with plerixafor as a single agent for allogeneic PBPC transplantation. Donors were treated with single-dose plerixafor 240 mg/kg s.c. and leukapheresis was initiated 4 h later.…”

Section: Chemokine Axis Mobilizationmentioning

confidence: 95%

Novel agents and approaches for stem cell mobilization in normal donors and patients

Bakanay

Demirer

2011

Bone Marrow Transplant

View full text Add to dashboard Cite

In spite of the safety and efficiency of the classical mobilization protocols, recombinant human G-CSF ± chemotherapy, there is still a considerable amount of mobilization failures (10--30%), which warrant novel agents and approaches both in an autologous and an allogeneic transplant setting. Attempts to improve CD34 þ yields by using several cytokines and growth factors as adjuncts to G-CSF could not change the standard approaches during the last decade, either because of inefficiency or the adverse events encountered with these agents. As a long-acting G-CSF analog, pegfilgrastim has the advantages of an earlier start of apheresis, reduction in the number of apheresis procedures as well as a reduced number of injections as compared with unconjugated G-CSF. However, dosing and cost-effectiveness especially in cytokine-only mobilizations require further investigation. As interactions between hematopoietic stem cells and the BM microenvironment are better understood, new molecules targeting these interactions are emerging. Plerixafor, which started its journey as an anti-HIV drug, recently ended up being a popular stem cell mobilizer with the ability of rapid mobilization and gained approval as an adjunct to G-CSF for poor mobilizers. At present, it is challenging to search for the best approach by using the available drugs with appropriate timing to provide sufficient CD34 þ yield after an initial mobilization attempt, and in a cost-effective manner thereby avoiding further mobilization attempts and exposure to chemotherapy. Approaches not only for increasing stem cell yield, but also aiming to improve the quality of graft content and the associated transplantation outcomes are promising areas of research.

show abstract

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

Cited by 20 publications

References 17 publications

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program

Novel agents and approaches for stem cell mobilization in normal donors and patients

Contact Info

Product

Resources

About